Clinical impact of atypical antipsychotics: Prospective 6-month study of inpatients treated by risperidone or olanzapine;Impact clinique des neuroleptiques atypiques: Étude prospective sur 6 mois en milieu hospitalier de patients traités par rispéridone ou olanzapine

Therapie

Volumn 56, Issue 6, 2001, Pages 645-652

  Hamel, B ^a   Courtet, P ^a   Vergnes, C ^a   Boulenger, J P ^a  

^a Centre Hospitalier de Haguenau   (France)

Author keywords

Neuroleptic; Olanzapine; Pharmacoepidemiology; Risperidone; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RAT STRAIN; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISPERIDONE; SCHIZOPHRENIA;

EID: 0035709886     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Symptoms of schizophrenia: Methods, meanings and mecanisms
2. Assessment of enduring deficit and negative symptoms subtypes in schizophrenia
3. Causes of neuroleptic noncompliance
4. From noncompliance to collaboration in the treatment of schizophrenia
5. A Canadian multicenter placebo-controlled study of fixed dose of risperidone and haloperidol in the treatment of chronic schizophrenic patients
6. Risperidone in the treatment of schizophrenia
7. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
8. Negative symptoms: A path analytic approach to a double-blind placebo- and halo-peridol-controlled clinical trial with olanzapine
9. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study)
10. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: Results of a prospective pharmacoepidemiologic study
11. Symptom correlates of global measures of severity in schizophrenia
12. Screening for cognitive toxicity of anticholinergic drugs
13. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
14. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia
15. Side effect profiles of new antipsychotic agents
16. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with loan or haloperidol
17. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder
18. Weight gain associated with neuroleptic medication: A review
19. Weight gain: Side effect of atypical neuroleptics?
20. Critical analysis and comparison of the side-effect and safety profiles of the new antipsychotics
21. The relationship of pharmacology to side effects
22. The cognitive efficacy of atypical antipsychotics in schizophrenia
23. Cognitive effects of conventional and atypical antipsychotics in schizophrenia
24. Enquête prospective d'opinion de la rispéridone
25. Which atypical antipsychotic?
26. La parole aux patients schizophrènes: Enquête européenne
27. Long-term treatment of chronic schizophrenia with risperidone: An open-label, multicenter study of 386 patients
28. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia